Research reveals promising strategy for treating tuberculosis

March 13, 2014 by Jennifer Dimas

(Medical Xpress)—Research at Colorado State University reveals that even the most intractable cases of tuberculosis might be effectively battled with a new drug cocktail combining conventional antibiotics and nontoxic compounds that mimic those found in some sea sponges.

Promising initial results of studies by Randall Basaraba and his colleagues recently were published in Pathogens and Disease, the journal of the Federation of European Microbiological Societies. The research is significant because TB, an infectious respiratory disease, kills an estimated 1.5 million people worldwide each year.

"TB remains a dire problem in many resource-poor regions of the world," said Basaraba, an investigator in the world-renowned CSU Mycobacteria Research Laboratories. "With one-third of the human population infected with the bacteria that causes tuberculosis, and with the emergence of drug-resistant strains of the bacteria, there is an urgent need to develop better treatment strategies and to discover the next generation of new antimicrobial drugs."

This message will be among those highlighted during awareness-raising events on World TB Day on March 24.

Basaraba's research project, funded by a $1.8 million grant from the National Institutes of Health, is aimed at developing more effective treatments for tuberculosis. He is directing the study in collaboration with other scientists in the CSU Mycobacteria Research Laboratories and with colleague Christian Melander, a University Faculty Scholar and the Howard J. Schaeffer Distinguished University Professor of Chemistry at North Carolina State University.

Basaraba and Melander began collaborating when they discovered their research groups were working on complementary pieces of the same puzzle: Both are interested in bacteria that cluster together, forming communities that protect them from antibiotics.

Melander's group has worked for several years to develop compounds that could break up these bacterial communities. In the course of this work, they found a remarkably clean sea sponge and successfully modified the responsible compound to create a new class of compounds capable of dispersing communities of bacteria.

Meanwhile, Basaraba's group was focused on developing a new laboratory model for studying Mycobacterium (Mtb), the pathogen that causes TB. Traditional laboratory models allowed scientists to study individual free-floating Mtb, but did not allow bacteria to form communities as they do in human and animal hosts.

The team's unique model allows bacteria to group, permitting the scientists to show that not all Mtb bacteria are equally susceptible to antibiotics. Individual bacteria multiply at a normal rate; when those same bacteria form communities, they adopt a slower multiplication rate.

Basaraba's team found that while the individual bacteria are susceptible to conventional TB drugs, the slower metabolism of the grouped bacteria enable them to survive high doses of antibiotics.

The new class of compounds developed by Melander's group, together with the new laboratory model developed by Basaraba's group, have enabled the researchers to try an approach fundamentally different from other TB treatment strategies: Using the new model, the researchers combined their compounds with antibiotics to study effects on Mtb.

Initial results show that the new compounds successfully break apart communities of bacteria, thereby rendering individual susceptible to conventional TB drugs. The compounds also inhibited the formation of new Mtb communities.

The scientists will continue testing the novel combination to determine whether the new compounds, combined with antibiotics, can shorten treatment duration and effectively eradicate drug-tolerant Mtb.

"Our hope is that this new strategy will increase the effectiveness of existing antimicrobial drugs by reducing disease relapse, and will prevent the continued emergence of multidrug-resistant Mtb strains," Basaraba said.

Explore further: Assay for pulmonary tuberculosis and rifa mpicin resistance in adults

Related Stories

Team develops way to make old antibiotic work against TB

January 27, 2014

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer. The drugs increased survival ...

Vinegar kills tuberculosis and other mycobacteria

February 25, 2014

The active ingredient in vinegar, acetic acid, can effectively kill mycobacteria, even highly drug-resistant Mycobacterium tuberculosis, an international team of researchers from Venezuela, France, and the US reports in mBio, ...

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.